Critical Limb Ischemia Clinical Trial
Official title:
An Open-label, Non-Randomized, Patient Funded, Multi-Center Study to Assess the Safety and Effects of Autologous Adipose-Derived Stromal Cells Via Intramuscular Injections for the Treatment of Critical Limb Ischemia
Verified date | July 2017 |
Source | Ageless Regenerative Institute |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
This is an open-label, non-randomized, multi center, patient sponsored study of
Adipose-Derived Stromal Cell (ASC) implantation via intramuscular injections in patients who
have critical limb ischemia not amenable for revascularization.
The intent of this clinical study is to answer the questions: 1) Is the proposed treatment
safe and 2) Is treatment effective in improving the disease pathology of patients with
diagnosed critical limb ischemia ASCs will be collected from the patient's adipose-derived
tissue (body fat). Using local anesthesia, Liposuction will be performed to collect the
adipose tissue specimen. The adipose tissue is then transferred to the laboratory for
separation of the adipose tissue derived stem cells. In addition, peripheral blood will be
collected for isolation of platelet rich plasma, which are then combined with the ASC's for
intramuscular injection into the lower limb.
Status | Withdrawn |
Enrollment | 0 |
Est. completion date | June 2017 |
Est. primary completion date | April 2017 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility |
Inclusion Criteria: - Age ~ 18 years - Existence of limb ischemia, with clinical presentation corresponding to Rutherford Categories 2-6 as defined in the reporting standards adopted by \ the Society of Vascular Surgeons, or corresponding to the Leriche-Fontaine Classification, stages II, III, or IV - Patients with, ischemia and ischemic ulceration provided patient have angiographic evidence of vascular compromise and is not a candidate for revascularization - Stable and on optimal medical management for > 60 days as follows: - Clopidogrel/aspirin therapy or other anticoagulation therapy, cholesterol- lowering agent, and/or antihypertensive medication - Hematocrit = 28.0%, White Blood Cell count =14,000, Platelet count = 50,000 - Creatinine = 2.5 mg/dL, and INR = 1.6 (unless taking warfarin) or PTT < 1.5× control (to avoid bleeding complications). INR values for patients taking warfarin will be corrected prior to the procedure - Patient meets at least one of the following diagnostic criteria for the index limb: 1. ABI<.5mmHg 2. TcpO2 <20 mm Hg when lying down and breathing room air, if available 3. Or, nonhealing ulcer due to local arterial compromise with no opportunity for revascularization - At least one non-healing distal extremity ischemic ulcer as confirmed by a vascular surgeon - Up to date on all age and gender appropriate cancer screening per American Cancer Society Exclusion Criteria: - Female who is pregnant or nursing, or is of childbearing potential and not using a reliable method of contraception - Any medical problems contraindicating tumescent syringe liposuction - Life expectancy < 6 months - Patient determined to be nonsurgical candidate due to reasons such as 1. High-risk medical conditions 2. Unstable cardiac disease 3. Stroke or transient ischemic attack leading to limitations in lower extremities or occurring within 180 days prior to the initial screening visit 4. Severe arthritis or other musculoskeletal disorder. - Systolic blood pressure (supine) = 90 mmHg - Resting heart rate > 100 bpm - Poorly controlled diabetes mellitus (HgbA1c > 10%) - Life-threatening complications of limb ischemia necessitating immediate amputation - Uncorrected iliac artery occlusion on index side unless corrected with stent - Extensive necrosis of the index limb or other conditions that make amputation inevitable (Rutherford Category 6) - Active clinical infection within one week of enrollment - Treatment with immunosuppressant drugs - Known drug or alcohol dependence, or any other factors which will interfere with the study conduct or interpretation of the results - Not suitable to participate in the opinion of the principal investigator - History cancer (other than non-melanoma skin cancer or in situ cervical cancer) within five years preceding study entry - Unwilling and/or not able to give written informed consent |
Country | Name | City | State |
---|---|---|---|
United States | Ageless Institute | Miami | Florida |
Lead Sponsor | Collaborator |
---|---|
Ageless Regenerative Institute |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Other | Change from baseline in Quality of Life | King's College Hospital's Vascular Quality of Life Questionnaire | 3 months, 6 months | |
Primary | Improvement from baseline in perfusion as measured by ankle-brachial index and collateral artery number | Contrast Angiography | 6 months | |
Primary | Number of adverse events reported | 6 months | ||
Secondary | Improvement from baseline in improvement or resolution of ulcer or gangrene | Visual assessment | 3 months, 6 months | |
Secondary | Limb Salvage | Assessed with doppler to measure blood flow to the affected area. | 3 months and 6 months |
Status | Clinical Trial | Phase | |
---|---|---|---|
Active, not recruiting |
NCT03987061 -
MOTIV Bioresorbable Scaffold in BTK Artery Disease
|
N/A | |
Recruiting |
NCT03668353 -
Recombinant SeV-hFGF2/dF Injection for PAOD
|
Phase 1 | |
Recruiting |
NCT04110964 -
Evaluation of Safety and Tolerability of Libella Gene Therapy for Critical Limb Ischemia: AAV- hTERT
|
Phase 1 | |
Not yet recruiting |
NCT03994666 -
Cell Therapy in Critical Limb Ischemia
|
Phase 2 | |
Recruiting |
NCT02389023 -
Comparison of Prevena Negative Pressure Incision Management System vs. Standard Dressing After Vascular Surgery
|
N/A | |
Not yet recruiting |
NCT02498080 -
Drug Eluting Balloons PTA in Infra-popliteal Arteries in Patients With Critical Limb Ischemia
|
N/A | |
Completed |
NCT02539940 -
Elutax-SV Drug-eluting Balloons for Below-the-knee Treatment
|
||
Recruiting |
NCT02239419 -
Evaluation of Carbothera in the Treatment of Foot Ulcers
|
N/A | |
Recruiting |
NCT01938872 -
Evaluating the Effectiveness of Paclitaxel-eluting Balloons for Below-the-knee Angioplasty in Patients With Critical Limb Ischemia
|
N/A | |
Active, not recruiting |
NCT01211925 -
Distal Venous Arterialisation of Ischemic Limb
|
Phase 2/Phase 3 | |
Completed |
NCT02454231 -
Monocentric Trial: Stem Cell Emergency Life Threatening Limbs Arteriopathy (SCELTA)
|
Phase 2/Phase 3 | |
Completed |
NCT01758874 -
Study to Explore the Effect of Lowering Blood Viscosity in Patients With Treatment-resistant Critical Limb Ischemia
|
Phase 2 | |
Completed |
NCT02475200 -
Phoenix Post-Approval Registry - Using the Phoenix Atherectomy Systems
|
||
Recruiting |
NCT04583436 -
Efficacy and Safety Comparison of the Open and Endovascular Surgical Methods for the Treatment of Long Atherosclerotic Lesions of the Femoral-popliteal Segment Below the Knee, TASC D in Patients With Critical Limb Ischemia
|
N/A | |
Completed |
NCT04071782 -
Investigating the Safety and Efficacy of the Treatment With the Selution Sirolimus Coated Balloon in TASC C and D Tibial Occlusive Disease in Patients With Critical Limb Ischemia From Singapore
|
N/A | |
Completed |
NCT03669458 -
Feasibility Clinical Trial Using the SPUR System to Demonstrate Safety and Efficacy.
|
N/A | |
Not yet recruiting |
NCT06007469 -
Pedal Acceleration Time (PAT) as a Measure of Foot Perfusion
|
||
Recruiting |
NCT04110327 -
An All-Comers Observational Study of the MicroStentâ„¢ Peripheral Vascular Stent System in Subjects With Peripheral Arterial Disease
|
||
Completed |
NCT02260622 -
Pilot Study to Examine the Use of Rivaroxaban After Angioplasty for Critical Limb Ischemia
|
Phase 2 | |
Recruiting |
NCT02054416 -
External Compression Therapy for Secondary Prevention of Lower-Limb Loss and Cardiovascular Mortality
|
N/A |